Statin dose in Asians: is pharmacogenetics relevant? (Q37951651)

25 August 2017

title

Statin dose in Asians: is pharmacogenetics relevant? (English)

1 reference

25 August 2017

Ping Wang

1

1 reference

25 August 2017

publication date

1 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

12

1 reference

25 August 2017

issue

11

1 reference

25 August 2017

page(s)

1605-1615

1 reference

A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan

25 August 2017

cites work

1 reference

Statin effects on LDL and HDL cholesterol in South Asian and white populations.

21 January 2018

1 reference

Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies.

21 January 2018

1 reference

Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease

21 January 2018

1 reference

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

21 January 2018

1 reference

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

21 January 2018

1 reference

Effects of rosuvastatin on low-density lipoprotein cholesterol and plasma lipids in Asian patients with hypercholesterolemia

21 January 2018

1 reference

Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

21 January 2018

1 reference

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.

21 January 2018

1 reference

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 January 2018

1 reference

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

21 January 2018

1 reference

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

21 January 2018

1 reference

Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

21 January 2018

1 reference

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers

21 January 2018

1 reference

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

21 January 2018

1 reference

Ethnic differences in statin disposition

21 January 2018

1 reference

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

21 January 2018

1 reference

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

The SLCO1B1*5 genetic variant is associated with statin-induced side effects

21 January 2018

1 reference

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

21 January 2018

1 reference

CYP2D6*4 polymorphism is associated with statin-induced muscle effects

21 January 2018

1 reference

A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

21 January 2018

1 reference

Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy

21 January 2018

1 reference

A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin

21 January 2018

1 reference

Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients

21 January 2018

1 reference

Myopathy, statins, and vitamin D deficiency

21 January 2018

1 reference

Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence

21 January 2018

1 reference

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

21 January 2018

1 reference

Genetic variants in the KIF6 region and coronary event reduction from statin therapy

21 January 2018

1 reference

Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial

21 January 2018

1 reference

Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.

21 January 2018

1 reference

Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.

21 January 2018

1 reference

KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study

21 January 2018

1 reference

Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention

21 January 2018

1 reference

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

21 January 2018

1 reference

Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins

21 January 2018

1 reference

Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors

21 January 2018

1 reference

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients

21 January 2018

1 reference

Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients

21 January 2018

1 reference

Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

21 January 2018

1 reference

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

21 January 2018

1 reference

CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women

21 January 2018

1 reference

The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease

21 January 2018

1 reference

Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease

21 January 2018

1 reference

Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.

21 January 2018

1 reference

Lipid-lowering response to statins is affected by CYP3A5 polymorphism

21 January 2018

1 reference

A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.

21 January 2018

1 reference

Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment

21 January 2018

1 reference

Pharmacogenetic study of statin therapy and cholesterol reduction

21 January 2018

1 reference

(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients

21 January 2018

1 reference

The role of HMGCR alternative splicing in statin efficacy

21 January 2018

1 reference

Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.

21 January 2018

1 reference

Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism

21 January 2018

1 reference

Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment

21 January 2018

1 reference

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol

21 January 2018

1 reference

Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia

21 January 2018

1 reference

Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study o

21 January 2018

1 reference

Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia

21 January 2018

1 reference

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

21 January 2018

1 reference

Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study

21 January 2018

1 reference

A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).

21 January 2018

1 reference

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).

21 January 2018

1 reference

Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT).

21 January 2018

1 reference

Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy: long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study

21 January 2018

1 reference

Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).

21 January 2018

1 reference

ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin

21 January 2018

1 reference

Global analysis of genetic variation in SLCO1B1.

21 January 2018

1 reference

Association between variants in the genes for leptin, leptin receptor, and proopiomelanocortin with chronic heart failure in the Czech population.

21 January 2018

1 reference

ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations

21 January 2018

1 reference

Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.

21 January 2018

1 reference

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition

21 January 2018

1 reference

Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.

21 January 2018

1 reference

Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study

21 January 2018

1 reference

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin

21 January 2018

1 reference

Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study

21 January 2018

1 reference

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.11.98

1 reference

release_s5b7pjoqebeknhq67jyxd7vn2e

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s5b7pjoqebeknhq67jyxd7vn2e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference